

OVERVIEW

- Catalyst
- Summary

EXECUTIVE SUMMARY

- Strategic scoping and focus
- Datamonitor key findings
- Related reports

MARKET DEFINITION

- Market definition for prostate cancer
- Forecast methodology and assumptions
 - Methodology flow
 - Patent expiries
 - New product launches

MARKET OVERVIEW AND CONTEXT

- Current and future market dynamics overview
 - Value of the market will increase through 2020
 - Antihormonals will remain the most dominant market class until 2020
 - New product launches will drive market growth
 - Growing patient populations highlight the need for drug sequencing
 - US sales and patient-based growth remain strongest throughout the forecast period
 - New therapies will dampen cytotoxic uptake in Japan
 - Little variation between uptake rates across the five major EU markets

PRODUCT FORECASTS

- Zytiga (abiraterone acetate; Johnson & Johnson)
 - Forecast assumptions
 - Zytiga forecast 2011–20
- Docetaxel
 - Forecast assumptions
 - Docetaxel forecast 2011–20
- Provenge (sipuleucel-T; Dendreon)
 - Forecast assumptions
 - Provenge forecast 2011–20
- Leuprolide
 - Forecast assumptions
 - Leuprolide forecast 2011–20
- Bicalutamide
 - Forecast assumptions
 - Bicalutamide forecast 2011–20
- Goserelin
 - Forecast assumptions

Goserelin forecast 2011–20
MDV3100 (Medivation)
Forecast assumptions
MDV3100 forecast 2011–20
TAK-700 (Takeda)
Forecast assumptions
TAK-700 forecast 2011–20
Tasquinimod (Active Biotech)
Forecast assumptions
Tasquinimod forecast 2011–20
Cabozantinib (Exelexis)
Forecast assumptions
Cabozantinib forecast 2011–20

BIBLIOGRAPHY

Journal papers
Websites
Datamonitor reports

APPENDIX

Contributing experts
Forecast methodology
Volume and value forecast methodology
Price and compliance assumptions
Physician sample breakdown
Report methodology

TABLES

Table: Summary of therapeutic classes in prostate cancer by Anatomical Therapeutic Chemical code, 2011
Table: Summary of the ICD-10 codes used to define prostate cancer, 2011
Table: Patent expiry dates for key marketed brands in prostate cancer, 2011
Table: Estimated launch dates for key late-stage pipeline products and marketed brands in prostate cancer in the seven major markets, 2011–20
Table: Prostate cancer molecule sales in the seven major markets (\$m), 2011–20
Table: Incident prostate cancer cases in the seven major markets, 2010–20
Table: Prostate cancer sales by molecule and class in the US (\$m), 2011–20
Table: Prostate cancer sales by molecule and class in Japan (\$m), 2011–20
Table: Prostate cancer sales by molecule and class in the five major EU markets (\$m), 2011–20
Table: Key prostate cancer drug sales across the seven major markets, 2011 and 2020
Table: Zytiga (abiraterone acetate; Johnson & Johnson) sales for prostate cancer, by country (\$m), 2011–20
Table: Docetaxel sales for prostate cancer, by country, (\$m), 2011–20

Table: Provenge (sipuleucel-T; Dendreon) sales for prostate cancer, by country (\$m), 2011–20

Table: Leuprolide sales for prostate cancer, by country (\$m), 2011–20

Table: Bicalutamide sales for prostate cancer, by country (\$m), 2011–20

Table: Goserelin sales for prostate cancer, by country (\$m), 2011–20

Table: MDV3100 (Medivation) sales for prostate cancer, by country (\$m), 2011–20

Table: TAK-700 (Takeda) sales for prostate cancer, by country (\$m), 2011–20

Table: Tasquinimod (Active Biotech) sales for prostate cancer, by country (\$m), 2011–20

Table: Cabozantinib (Exelexis) sales for prostate cancer, by country (\$m), 2011–20

FIGURES

Figure: Patient based forecast methodology for prostate cancer, 2011

Figure: Prostate cancer market forecast across the seven major markets, by country (\$m), 2011–20

Figure: Prostate cancer sales in the seven major markets, by therapy type (\$m), 2011–20

Figure: Distribution of market share across the seven major markets, by molecule, 2020

Figure: Timeline: approval/launch dates of key prostate cancer therapies, 2011–20

Figure: Prostate cancer market value in the US, by class (\$m), 2011–20

Figure: Prostate cancer market value in Japan, by class (\$m), 2011–20

Figure: Prostate cancer market value in the five major EU markets, by class (\$m), 2011–20

Figure: Key prostate cancer drug sales in the seven major markets, 2011–20

Figure: Zytiga (abiraterone acetate; Johnson & Johnson) sales for prostate cancer, by country (\$m), 2011–20

Figure: Docetaxel sales for prostate cancer, by country (\$m), 2011–20

Figure: Provenge (sipuleucel-T; Dendreon) sales for prostate cancer, by country (\$m), 2011–20

Figure: Leuprolide sales for prostate cancer, by country (\$m), 2011–20

Figure: Bicalutamide sales for prostate cancer, by country (\$m), 2011–20

Figure: Goserelin sales for prostate cancer, by country (\$m), 2011–20

Figure: MDV3100 (Medivation) sales for prostate cancer, by country (\$m), 2011–20

Figure: TAK-700 (Takeda) sales for prostate cancer, by country (\$m), 2011–20

Figure: Tasquinimod (Active Biotech) sales for prostate cancer, by country (\$m), 2011–20

Figure: Cabozantinib (Exelexis) sales for prostate cancer, by country (\$m), 2011–20